Compare AstraZeneca plc (AZN) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Robinhood Markets, Inc. — how do they compare? AstraZeneca plc trades at $158.57 (market cap $248.14B), while Robinhood Markets, Inc. trades at $95.18 (market cap $84.86B). The key difference: AstraZeneca plc is far larger — about 2.9× Robinhood Markets, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| AZN | HOOD | |
|---|---|---|
Market Cap | $248.14B | $84.86B |
Sector | Health | Technology |
52-Week High | $209.48 | $152.46 |
52-Week Low | $147.06 | $65.16 |
Enterprise Value | $275.41B | $91.40B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Robinhood Markets (HOOD) trades at $94.40, down 0.13% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 results with revenue growth of 32% and earnings beating expectations, driven by diversification beyond crypto into event contracts and international expansion. Valuation metrics remain elevated with P/E of 41.76 and P/S of 17.6, reflecting premium pricing for growth prospects.
The outlook remains positive with analyst consensus pointing to significant upside (target $123.46), though near-term technical weakness and competitive pressures in the UK crypto expansion present risks. Revenue diversification and strong cash flow generation support long-term growth, but investors should monitor execution on international expansion and margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
